MDC CONNECTS 2021
Complex Medicines: 
Understanding Safety & Efficacy

15 June 2021  |  2 - 3PM BST

The medicines industry is in a period of change. While small molecule therapeutics still make up 90% of approved medicines, patient expectations are driving the industry towards targeted, precision treatments, which require a shift towards stratified, complex medicines with more challenging discovery and development needs.

© Medicines Discovery Catapult 2021. All rights reserved. Read our Privacy Policy

BACKGROUND

Physicochemical characterisation: new and novel approaches to understand the pharmacokinetics of complex drugs - Juliana Maynard, Lead Scientist (MDC)
Determining efficacy in vivo - Jenny Worthington, Co-Founder and Director of Science (Axis Bio)
Do complex medicines raise different challenges from a safety perspective? - Richard Knight, Director and Co-Founder (ApconiX)

AGENDA

BOOK YOUR PLACE

ABOUT THE PRESENTERS

OTHER WEBINARS IN THE SERIES

Complex Medicines: A Glance at Novel Drug Delivery Systems
8 June 2021  |  2 - 3PM BST
Register >

Complex Medicines: Selection and Characterisation of the Lead
18 May 2021  |  2 - 3PM BST
Register >

Complex Medicines: Ready for the Clinic/Scaling up for Success
22 June 2021  |  2 - 3PM BST
Register >

Complex Medicines: Understanding the Interplay with Biological Systems
25 May 2021  |  2 - 3PM BST
Register >

Dr Juliana Maynard
Juliana Maynard is Lead Scientist in Pre-clinical Imaging at MDC. She works with a wide range of molecular imaging modalities including PET, SPECT, CT and ultrasound. Previously she was Head of Imaging Services at Alderley Imaging and worked at AstraZeneca for 9 years. Juliana has a PHD in neuroendocrinology from the University of Edinburgh.

Complex Medicines: Why, What, When? Opportunities and Challenges
11 May 2021  |  2 - 3PM BST
Register >

Dr Sarah Brockbank
Sarah Brockbank is Lead Scientist of External Drug Discovery at the Medicines Discovery Catapult. Here she supports SMEs develop and execute drug discovery projects and provides the project management of virtual preclinical programmes by connecting clients with expertise and capabilities.

 
Sarah has 30 years’ experience in the pharmaceutical industry. She is a molecular biologist with a focus mainly in target identification & validation and has worked across a broad range of disease areas. Sarah was a Drug Discovery Project Leader at AstraZeneca and she also has extensive experience in collaboration management and project management of large public-private consortia.

Here experts describe how to establish preclinical safety and efficacy data for complex medicines and how this compares with conventional drug discovery.

Dr Jenny Worthington
Dr Jenny Worthington is Co-Founder and Director of Science at Axis Bio. She gained her PhD from the University of Ulster, Northern Ireland, in the area of cancer gene therapy, and worked through postdoctoral positions before establishing a research team in prostate cancer preclinical research. Jenny has used her background in cancer research and drug discovery to move into a commercial setting. Using her knowledge and experience she has nurtured excellence in a team of scientists who provide clients with an excellent preclinical service portfolio.

Richard Knight
Richard Knight is a director and co-founder of ApconiX, a company providing nonclinical safety consultancy and ion channel laboratory services, based at Alderley Park. Prior to starting ApconiX in 2015, he was senior director in Safety Assessment at AstraZeneca with more than 25 years of project experience. Richard has worked across multiple therapy areas involving small molecules, biologics, proteins and oligonucleotides and been involved in bringing over 35 new candidate drugs into clinical trials as well as 6 to market.